NEW YORK (GenomeWeb) – Roche said this week that its Ventana PD-L1 assay has been expanded for use in non-small cell lung cancer and metastatic urothelial carcinoma in countries that recognize CE marking, and where Roche's Tecentriq cancer immunotherapy is approved. The assay was previously approved by the US Food and Drug Administration as a complementary diagnostic for assessing patients with NSCLC and mUC being considered for treatment with Tecentriq. It uses immune cell and tumor cell staining within the tumor microenvironment to evaluate patients with PD-L1 status.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.